keytruda
Worldwide cancer spending tops $100 billion
May 5, 2015Research and Development, Sales and Marketing Cancer, IMS Health, keytruda, oncology
Over $100 billion was spent on cancer medicines across the world last year as a new generation of drugs begins …
EMA approves BMS’ Opdivo for advanced skin cancer
April 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer
Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …
Merck KGaA and Pfizer alliance begins lung cancer study
April 21, 2015Research and Development, Sales and Marketing Merck KGaA, Pfizer, avelumab, keytruda, oncology, opdivo
Merck KGaA and Pfizer have enrolled and treated the first patient in a late-stage study of their anti-PD1 cancer immunotherapy …
Merck seeks new Keytruda indication in US
April 20, 2015Sales and Marketing Cancer, FDA, NSCLC, PD-L1, US, keytruda, lung, pembrolizumab
Merck is seeking FDA approval for its successful melanoma drug Keytruda to be used treating lung cancer. The Supplemental Biologics …
Merck lines up early-stage Keytruda combo trial
April 1, 2015Research and Development, Sales and Marketing Cancer, Merck, entinostat, keytruda, pd1, pembrolizumab, syndax
Merck is planning for Keytruda’s future by launching early-stage trials of the drug in combination with an investigational treatment from …
Merck’s Keytruda trial stopped early after beating BMS’ Yervoy on survival
March 25, 2015Research and Development, Sales and Marketing BMS, Merck, Yervoy, ipilimumab, keytruda, pembrolizumab
A trial comparing two potential blockbuster cancer treatments has been stopped early, after Merck’s Keytruda beat BMS’ Yervoy in a …
Merck’s cancer drug sees first ever early access nod
March 11, 2015Sales and Marketing Cancer, ICR, Merck, eams, early access, keytruda, melanoma, oncology, pembrolizumab
Merck’s skin cancer drug Keytruda has become the first drug to be approved through the new Early Access to Medicines …
Merck and Eisai partner on cancer therapy trial
March 6, 2015Research and Development, Sales and Marketing Bayer, Cancer, FDA, Halaven, Lenvima, Merck, Stivarga, keytruda, oncology, pd1
Merck and Eisai are teaming up for collaborative trials to test the effects of using combinations of each company’s oncology …
BMS Opdivo trial scores early goal
January 14, 2015Research and Development, Sales and Marketing BMS, Merck, cancer nsclc, keytruda, nivolumab, opdivo
A late-stage trial of Bristol-Myers Squibb’s lung cancer drug Opdivo has been stopped early after showing promising results – but …
Lilly, BMS and Merck unite for cancer trials
January 13, 2015Research and Development, Sales and Marketing BMS, Cancer, Galunisertib, Merck, NSCLC, keytruda, lilly, oncology, opdivo
Lilly will test some of its compounds in combination with rival cancer drugs from Bristol-Myers Squibb and Merck, the companies …
Merck acquires Swiss firm OncoEthix
December 19, 2014Sales and Marketing Cancer, FDA, Merck, OTX015, cubist, keytruda, oncoethix, pembrolizumab
Hot on the heals of its Cubist buyout Merck has confirmed the acquisition of OncoEthix, a Swiss based firm which …
BMS therapeutic cancer vaccine given swift FDA appraisal
September 29, 2014Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, Vaccine, bristol myers-squibb, keytruda, melanoma, opdivo
Bristol-Myers Squibb has been granted a speedy review for its new cancer immunotherapy drug Opdivo by the FDA for patients …
Cancer drug gains first early UK access grant
September 17, 2014Research and Development, Sales and Marketing Cancer, NICE, UK, keytruda, oncology, pin, promising
A new type of cell therapy for cancer has become the first to be deemed by the UK government as …
BMS sues Merck over new melanoma drug
September 8, 2014Research and Development, Sales and Marketing BMS, FDA, Merck, PD-1 inhibitors, Yervoy, keytruda
Things are getting ugly between Bristol-Myers Squibb and Merck as the former company began legal proceedings against the latter over …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
